Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan
· Delayed Price · Currency is TWD 138.50
+12.50 (9.92%)
Apr 29, 2026, 1:30 PM CST
Lumosa Therapeutics Revenue
In the year 2025, Lumosa Therapeutics had annual revenue of 35.83M TWD, down -8.49%. Lumosa Therapeutics had revenue of 13.05M in the quarter ending December 31, 2025, a decrease of -34.11%.
Revenue
35.83M
Revenue Growth
-8.49%
P/S Ratio
588.97
Revenue / Employee
918.74K
Employees
39
Market Cap
21.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.83M | -3.32M | -8.49% |
| Dec 31, 2024 | 39.15M | -17.76M | -31.21% |
| Dec 31, 2023 | 56.92M | 30.27M | 113.63% |
| Dec 31, 2022 | 26.64M | 9.28M | 53.45% |
| Dec 31, 2021 | 17.36M | -4.29M | -19.81% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.03B |
| Oneness Biotech | 129.12M |
| AP Biosciences | 32.25M |
| Medigen Vaccine Biologics | 613.17M |
| Polaris Group | 40.60M |
| EirGenix | 1.01B |
| TaiMed Biologics | 611.35M |
| Locus Cell | 12.74M |